Patents by Inventor Matti Lepisto

Matti Lepisto has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9738632
    Abstract: A compound of formula Ia: The present invention relates to novel indazolyl derivatives, to pharmaceutical compositions comprising such derivatives, to processes for preparing such novel derivatives and to the use of such derivatives as medicaments.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: August 22, 2017
    Assignees: AstraZeneca AB, Bayer Pharma Aktiengesellschaft
    Inventors: Markus Berger, Hartmut Rehwinkel, Jan Dahmen, Anders Eriksson, Thomas Hansson, Nafizal Hossain, Per Tomas Klingstedt, Matti Lepisto, Stinabritt Nilsson, Martin Hemmerling, Karl Edman
  • Publication number: 20170081315
    Abstract: A compound of formula Ia: The present invention relates to novel indazolyl derivatives, to pharmaceutical compositions comprising such derivatives, to processes for preparing such novel derivatives and to the use of such derivatives as medicaments
    Type: Application
    Filed: December 2, 2016
    Publication date: March 23, 2017
    Inventors: Markus Berger, Hartmut Rehwinkel, Jan Dahmen, Anders Eriksson, Thomas Hansson, Nafizal Hossain, Per Tomas Klingstedt, Matti Lepisto, Stinabritt Nilsson, Martin Hemmerling, Karl Edman
  • Patent number: 9512110
    Abstract: A compound of formula Ia: The present invention relates to novel indazolyl derivatives, to pharmaceutical compositions comprising such derivatives, to processes for preparing such novel derivatives and to the use of such derivatives as medicaments
    Type: Grant
    Filed: November 19, 2014
    Date of Patent: December 6, 2016
    Assignees: AstraZeneca AB, Bayer Pharma Aktiengesellschaft
    Inventors: Markus Berger, Hartmut Rehwinkel, Jan Dahmen, Anders Eriksson, Thomas Hansson, Nafizal Hossain, Per Tomas Klingstedt, Matti Lepistö, Stinabritt Nilsson, Martin Hemmerling, Karl Edman
  • Publication number: 20150080434
    Abstract: A compound of formula Ia: The present invention relates to novel indazolyl derivatives, to pharmaceutical compositions comprising such derivatives, to processes for preparing such novel derivatives and to the use of such derivatives as medicaments
    Type: Application
    Filed: November 19, 2014
    Publication date: March 19, 2015
    Inventors: Markus Berger, Hartmut Rehwinkel, Jan Dahmen, Anders Eriksson, Thomas Hansson, Nafizal Hossain, Per Thomas Klingstedt, Matti Lepistö, Stinabritt Nilsson, Martin Hemmerling, Karl Edman
  • Patent number: 8916600
    Abstract: A compound of formula Ia: The present invention relates to novel indazolyl derivatives, to pharmaceutical compositions comprising such derivatives, to processes for preparing such novel derivatives and to the use of such derivatives as medicaments.
    Type: Grant
    Filed: June 6, 2012
    Date of Patent: December 23, 2014
    Assignees: Astrazeneca AB, Bayer Pharma Aktiengesellschaft
    Inventors: Markus Berger, Hartmut Rehwinkel, Jan Dahmén, Anders Eriksson, Thomas Hansson, Nafizal Hossain, Per Tomas Klingstedt, Matti Lepistö, Stinabritt Nilsson, Martin Hemmerling, Karl Edman
  • Publication number: 20120302617
    Abstract: A compound of formula Ia: The present invention relates to novel indazolyl derivatives, to pharmaceutical compositions comprising such derivatives, to processes for preparing such novel derivatives and to the use of such derivatives as medicaments.
    Type: Application
    Filed: June 6, 2012
    Publication date: November 29, 2012
    Inventors: Markus Berger, Hartmut Rehwinkel, Jan Dahmen, Anders Eriksson, Thomas Hansson, Nafizal Hossain, Per Tomas Klingstedt, Matti Lepistö, Stinabritt Nilsson, Martin Hemmerling, Karl Edman
  • Publication number: 20120252770
    Abstract: Compounds of formula (I): The present invention relates to novel indazolyl ester or amide derivatives, to pharmaceutical compositions comprising such derivatives, to processes for preparing such novel derivatives and to the use of such derivatives as medicaments
    Type: Application
    Filed: March 23, 2012
    Publication date: October 4, 2012
    Inventors: Markus Berger, Jan Dahmén, Karl Edman, Anders Eriksson, Balint Gabos, Thomas Hansson, Martin Hemmerling, Krister Henriksson, Svetlana Ivanova, Matti Lepistö, Darren McKerrencher, Magnus Munck af Rosenschöld, Stinabritt Nilsson, Hartmut Rehwinkel, Camilla Taflin
  • Patent number: 8211930
    Abstract: A compound of formula Ia: The present invention relates to novel indazolyl derivatives, to pharmaceutical compositions comprising such derivatives, to processes for preparing such novel derivatives and to the use of such derivatives as medicaments
    Type: Grant
    Filed: May 19, 2009
    Date of Patent: July 3, 2012
    Assignees: AstraZeneca AB, Bayer Schering Pharma AG
    Inventors: Markus Berger, Hartmut Rehwinkel, Jan Dahmén, Anders Eriksson, Thomas Hansson, Nafizal Hossain, Per Tomas Klingstedt, Matti Lepistö, Stinabritt Nilsson, Martin Hemmerling, Karl Edman
  • Patent number: 8153673
    Abstract: Compounds of the formula (I) wherein Z is SO2(N6) or N(R7)SO2 or N(R7)SO2N(R6) useful as metalloproteinase inhibitors, especially as inhibitors of MMP12.
    Type: Grant
    Filed: January 26, 2010
    Date of Patent: April 10, 2012
    Assignee: AstraZeneca AB
    Inventors: Anders Eriksson, Matti Lepistö, Michael Lundkvist, Magnus Munck Af Rosenschöld, Pavol Zlatoidsky
  • Patent number: 8143290
    Abstract: Compounds of formula (I): The present invention relates to novel indazolyl ester or amide derivatives, to pharmaceutical compositions comprising such derivatives, to processes for preparing such novel derivatives and to the use of such derivatives as medicaments.
    Type: Grant
    Filed: December 2, 2010
    Date of Patent: March 27, 2012
    Assignees: AstraZeneca AB, Bayer Schering Pharma Aktiengesellschaft
    Inventors: Markus Berger, Jan Dahmén, Karl Edman, Anders Eriksson, Balint Gabos, Thomas Hansson, Martin Hemmerling, Krister Henriksson, Svetlana Ivanova, Matti Lepistö, Darren McKerrecher, Magnus Munck af Rosenschöld, Stinabritt Nilsson, Hartmut Rehwinkel, Camilla Taflin
  • Publication number: 20120065173
    Abstract: Compounds of formula (I): or a pharmaceutically acceptable salt thereof; compositions comprising them, processes for preparing them and their use in medical therapy (for example modulating the glucocorticoid receptor in a warm blooded animal).
    Type: Application
    Filed: September 2, 2011
    Publication date: March 15, 2012
    Inventors: Markus Berger, Lena Bergström, Jan Dahmén, Anders Eriksson, Balint Gabos, Martin Hemmerling, Krister Henriksson, Svetlana Ivanova, Matti Lepistö, Stinabritt Nilsson, Camilla Taflin, Darren McKerrecher, Hartmut Rehwinkel
  • Publication number: 20110294766
    Abstract: The present invention provides compounds of formula (I) wherein R1, R2, R3, R4, R5 and R6 are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Application
    Filed: February 27, 2009
    Publication date: December 1, 2011
    Applicant: AstraZeneca AB
    Inventors: Frank Burkamp, Tesfaledet Mussie, Paul Andersson, Inga-Britt Andersson, Sumita Bhatacharyya, Håkan Bladh, Svetlana Ivanova, Matti Lepistö
  • Patent number: 8030340
    Abstract: Compounds of formula (I): or a pharmaceutically acceptable salt thereof, compositions comprising them, processes for preparing them and their use in medical therapy (for example modulating the glucocorticoid receptor in a warm blooded animal).
    Type: Grant
    Filed: November 21, 2007
    Date of Patent: October 4, 2011
    Assignees: AstraZeneca AB, Bayer Schering Pharma Aktiengesellschaft
    Inventors: Markus Berger, Lena Bergstrom, Jan Dahmen, Anders Eriksson, Balint Gabos, Martin Hemmerling, Krister Henriksson, Svetlana Ivanova, Matti Lepisto, Stinabritt Nilsson, Camilla Taflin, Hartmut Rehwinkel, Darren McKerrecher
  • Patent number: 7998984
    Abstract: The invention provides compounds of formula wherein R1, R3, R4, R5, R6, R14, X and W are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of human neutrophil elastase.
    Type: Grant
    Filed: May 7, 2007
    Date of Patent: August 16, 2011
    Assignee: AstraZeneca AB
    Inventors: Peter Hansen, Karolina Lawitz, Matti Lepistö, Hans Lönn, Asim Ray
  • Publication number: 20110160167
    Abstract: The present invention provides compounds of formula (I) wherein n, p, R1, R2, X1, X2, X3, R3a, R3b, R4, R5 and R6 are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Application
    Filed: December 18, 2008
    Publication date: June 30, 2011
    Applicant: AstraZeneca AB
    Inventors: Håkan Bladh, Karl Edman, Thomas Hansson, Karolina Lawitz, Matti Lepistö, Tesfaledet Mussie
  • Publication number: 20110130426
    Abstract: A compound of formula (I) or a pharmaceutically acceptable salt thereof; compositions comprising them, processes for preparing them and their use in medical therapy (for example modulating the glucocorticoid receptor in a warm blooded animal).
    Type: Application
    Filed: October 26, 2005
    Publication date: June 2, 2011
    Applicant: ASTRAZENECA AB
    Inventors: Håkan Bladh, Krister Henriksson, Vijaykumar Hulikal, Matti Lepistö
  • Publication number: 20110071194
    Abstract: Compounds of formula (I): The present invention relates to novel indazolyl ester or amide derivatives, to pharmaceutical compositions comprising such derivatives, to processes for preparing such novel derivatives and to the use of such derivatives as medicaments
    Type: Application
    Filed: December 2, 2010
    Publication date: March 24, 2011
    Inventors: Markus Berger, Jan Dahmén, Karl Edman, Anders Eriksson, Balint Gabos, Thomas Hansson, Martin Hemmerling, Krister Henriksson, Svetlana Ivanova, Matti Lepistö, Darren McKerrecher, Magnus Munck af Rosenschöld, Stinabritt Nilsson, Hartmut Rehwinkel, Camilla Taflin
  • Publication number: 20110003853
    Abstract: Compounds of the formula (I) wherein z is SO2 or SO, useful as metalloproteinase inhibitors, especially as inhibitors of MMP12.
    Type: Application
    Filed: July 6, 2010
    Publication date: January 6, 2011
    Inventors: Anders Eriksson, Matti Lepistö, Michael Lundkvist, Magnus Munck Af Rosenchöld, Pavol Zlatoidsky
  • Publication number: 20100273849
    Abstract: Compounds of the formula (I) wherein Z is SO2(N6) or N(R7)SO2 or N(R7)SO2N(R6) useful as metalloproteinase inhibitors, especially as inhibitors of MMP12.
    Type: Application
    Filed: January 26, 2010
    Publication date: October 28, 2010
    Inventors: Anders Eriksson, Matti Lepistö, Michael Lundkvist, Magnus Munck Af Rosenchöld, Pavol Zlatoidsky
  • Publication number: 20100197644
    Abstract: Compounds of formula (I): The present invention relates to novel indazolyl ester or amide derivatives, to pharmaceutical compositions comprising such derivatives, to processes for preparing such novel derivatives and to the use of such derivatives as medicaments
    Type: Application
    Filed: December 21, 2009
    Publication date: August 5, 2010
    Inventors: Markus Berger, Jan Dahmén, Karl Edman, Anders Eriksson, Balint Gabos, Thomas Hansson, Martin Hemmerling, Krister Henriksson, Svetlana Ivanova, Matti Lepistö, Darren McKerrecher, Magnus Munck af Rosenschöld, Stinabritt Nilsson, Hartmut Rehwinkel, Camilla Taflin